We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Elevance Health (ELV - Free Report) is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey.
Analysts have taken a bearish stance on the company’s outlook, landing the stock into a Zacks Rank #5 (Strong Sell).
Image Source: Zacks Investment Research
Let’s take a closer look at how the company stacks up.
ELV Cuts Guidance
ELV’s latest set of quarterly results came in weak, causing shares to plunge post-earnings. The company trimmed its current year outlook, with ELV also falling short of the Zacks Consensus EPS estimate by more than 3%.
The stock has underperformed in a big way overall in 2025, losing roughly 15% compared to the S&P 500’s 14.6% gain.
Image Source: Zacks Investment Research
Concerning the above-mentioned release, adjusted EPS fell 13% year-over-year, whereas sales of $49.4 billion grew 14% from the same period last year. Due to the ongoing and industry-wide impact of elevated cost trends in ACA and Medicaid, ELV now expects 2025 adjusted EPS well lower than the announced (and reaffirmed) guidance range of $34.15 - $34.85 given near the beginning of June.
The steep guidance cut after a reaffirmation just near the beginning of June is certainly notable. Below is a chart illustrating the company’s sales on a quarterly basis.
Image Source: Zacks Investment Research
Bottom Line
Negative earnings estimate revisions, stemming from trimmed guidance, paint a challenging picture for the company’s shares in the near term.
Elevance Health (ELV - Free Report) is a Zacks Rank #5 (Strong Sell), indicating that analysts have taken a bearish stance on the company’s earnings outlook.
For those seeking strong stocks, the best idea would be to focus on stocks with a Zacks Rank #1 (Strong Buy) or a Zacks Rank #2 (Buy) – these stocks sport a notably stronger earnings outlook paired with the potential to deliver explosive gains in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bear of the Day: Elevance Health (ELV)
Elevance Health (ELV - Free Report) is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey.
Analysts have taken a bearish stance on the company’s outlook, landing the stock into a Zacks Rank #5 (Strong Sell).
Image Source: Zacks Investment Research
Let’s take a closer look at how the company stacks up.
ELV Cuts Guidance
ELV’s latest set of quarterly results came in weak, causing shares to plunge post-earnings. The company trimmed its current year outlook, with ELV also falling short of the Zacks Consensus EPS estimate by more than 3%.
The stock has underperformed in a big way overall in 2025, losing roughly 15% compared to the S&P 500’s 14.6% gain.
Image Source: Zacks Investment Research
Concerning the above-mentioned release, adjusted EPS fell 13% year-over-year, whereas sales of $49.4 billion grew 14% from the same period last year. Due to the ongoing and industry-wide impact of elevated cost trends in ACA and Medicaid, ELV now expects 2025 adjusted EPS well lower than the announced (and reaffirmed) guidance range of $34.15 - $34.85 given near the beginning of June.
The steep guidance cut after a reaffirmation just near the beginning of June is certainly notable. Below is a chart illustrating the company’s sales on a quarterly basis.
Image Source: Zacks Investment Research
Bottom Line
Negative earnings estimate revisions, stemming from trimmed guidance, paint a challenging picture for the company’s shares in the near term.
Elevance Health (ELV - Free Report) is a Zacks Rank #5 (Strong Sell), indicating that analysts have taken a bearish stance on the company’s earnings outlook.
For those seeking strong stocks, the best idea would be to focus on stocks with a Zacks Rank #1 (Strong Buy) or a Zacks Rank #2 (Buy) – these stocks sport a notably stronger earnings outlook paired with the potential to deliver explosive gains in the near term.